About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Bilateral DLPC tDCS in Drug-resistant Migraine

NCT06079801·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Clínica de Intervención en Neurociencias

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

diagnosis of high-frequency and/or chronic migraines, according to the diagnostic criteria of the ICHD-III,
failure to more than 3 preventive drugs
stable pharmacological treatment (\> 6 months without changes),
absence of other neurological or medical pathological conditions,
written informed consent.

You may not be if

seizures
significant cognitive impairment that prevents following orders and understanding instructions (Mini-Mental State Examination \< 23)
pregnancy
aphasia or limitations in communication,
metallic cranial implants
another neurological or psychiatric pathology
diagnosis of another type of migraine.

The record

StatusCompleted

PhaseNo phase

Taking part36

StartedOct 2021

UpdatedOct 17, 2023

Conditions

Where1

Clinica de Intervencion en Neurociencias
Talavera de la Reina, Toledo, Spain

Clareo Health | Bilateral DLPC tDCS in Drug-resistant Migraine